Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00829465 | Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma | completed | Phase 4 | 400 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Apr 1, 2016 | clinicaltrials |
| NCT00834158 | Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC(TACEPVE) | completed | N/A | 20 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 |
| clinicaltrials |
| NCT00849264 | Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients | completed | Phase 2 | 120 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00851968 | A Trial of Complete Versus Selective HepaticVascular Clamping in Hepatectomy | completed | N/A | 320 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT01786980 | The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related Gene | completed | — | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02338297 | Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC | unknown | Phase 3 | 236 | Nanjing Medical UniversityOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02586285 | Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma | unknown | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00817895 | Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence | completed | N/A | 150 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01643447 | Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC) | completed | N/A | 200 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01717066 | the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma(Rg3) | completed | N/A | 480 | ShenFengOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01860222 | Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma | unknown | N/A | 160 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01923948 | Preoperative Pain Control in Liver Surgery Patients | completed | N/A | 40 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02525952 | Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System | unknown | N/A | 320 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02525965 | The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma | unknown | N/A | 194 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02587884 | Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH | unknown | Phase 1 | 180 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02724267 | Targeted Internal Radiation Therapy in Advanced HCC Patients. | completed | N/A | 200 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02724332 | Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC | completed | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02724345 | Postoperative Adjuvant TACE Treatment in CK18 Positive Patients | completed | — | 320 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02724358 | Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1 | completed | N/A | 320 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02724436 | Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma | completed | N/A | 200 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02724475 | Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | completed | N/A | 180 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02150317 | Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma(TACE) | unknown | N/A | 180 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 29, 2016 | clinicaltrials |
| NCT02718235 | Prospective, Multicenter HCCIS Evaluation Study(HCCIS) | unknown | — | 200 | University of RegensburgOTHER | 0 | Mar 24, 2016 | clinicaltrials |
| NCT02715362 | A Study of GPC3 Redirected Autologous T Cells for Advanced HCC(GPC3-CART) | unknown | Phase 1 / Phase 2 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Mar 22, 2016 | clinicaltrials |
| NCT02640924 | Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular Carcinoma | unknown | Phase 3 | 166 | Chang Gung Memorial HospitalOTHER | 1 | Mar 21, 2016 | clinicaltrials |
| NCT02709070 | Resection+Highly Purified CTL Versus Resection Alone for HCC | unknown | Phase 3 | 210 | Sun Yat-sen UniversityOTHER | 0 | Mar 16, 2016 | clinicaltrials |
| NCT02537158 | Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection | unknown | N/A | 90 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 15, 2016 | clinicaltrials |
| NCT02210182 | A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma | completed | Phase 1 | 29 | Oncozyme Pharma Inc.INDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT00877071 | LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed(HCC) | completed | Phase 2 | 2 | University of PittsburghOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT00987935 | A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients | completed | Phase 2 | 134 | Boehringer IngelheimINDUSTRY | 2 | Mar 10, 2016 | clinicaltrials |
| NCT01147380 | Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation(MIAMINK) | completed | Phase 1 | 18 | Seigo NishidaOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02702323 | Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study | unknown | Phase 2 / Phase 3 | 40 | Zhejiang Cancer HospitalOTHER | 0 | Mar 8, 2016 | clinicaltrials |
| NCT02101593 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | completed | Phase 1 | 8 | Polaris GroupINDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT00055692 | Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT02678013 | RFA+Highly-purified CTL vs. RFA Alone for Recurrent HCC | unknown | Phase 3 | 210 | Ming KuangOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00582400 | A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver | terminated | Phase 2 | 9 | The University of Texas Medical Branch, GalvestonOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT01539681 | Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy(STELLA) | completed | — | 234 | BayerINDUSTRY | 1 | Feb 18, 2016 | clinicaltrials |
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | terminated | Phase 2 | 25 | Gabi Chiorean, MDOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT01594125 | Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 1 | Feb 12, 2016 | clinicaltrials |
| NCT01177631 | Proteomic Analysis of Human Hepatocellular Carcinoma | completed | N/A | 5 | Far Eastern Memorial HospitalOTHER | 1 | Feb 5, 2016 | clinicaltrials |
| NCT02672488 | Metformin Plus Sorafenib for Advanced HCC | unknown | Phase 2 | 82 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT01801852 | Autologous Natural Killer T Cells Infusion for the Treatment of Cancer | unknown | N/A | 300 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT02309788 | Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis(RHCC) | unknown | — | 100 | Guangxi Medical UniversityOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00712790 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 35 | Singapore Clinical Research InstituteOTHER | 4 | Jan 6, 2016 | clinicaltrials |
| NCT02403544 | Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma | unknown | Phase 1 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 5, 2016 | clinicaltrials |
| NCT02552745 | Preventive Effects of Parecoxib on Postoperative Complications in Hepatocellular Carcinoma Patients Undergoing Hepatic Transcatheter Arterial Chemoembolization | completed | — | 200 | Sun Yat-sen UniversityOTHER | 0 | Jan 5, 2016 | clinicaltrials |
| NCT02613156 | Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma | completed | — | 25 | Sun Yat-sen UniversityOTHER | 0 | Jan 5, 2016 | clinicaltrials |
| NCT02632006 | Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 40 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02638857 | Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT01140347 | A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib(REACH) | completed | Phase 3 | 565 | Eli Lilly and CompanyINDUSTRY | 27 | Dec 28, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Apr 1, 2016source: clinicaltrials